Abstract
Introduction of 13-valent pneumococcal conjugate vaccine in the United States was not associated with a significant change in prevalence of penicillin resistance in nonvaccine type serotypes because of the variable success of highly resistant serotypes. Differences in regional serotype distribution and serotype-specific resistance contributed to geographic heterogeneity of penicillin resistance.
Keywords:
13-valent pneumococcal conjugate vaccine; PCV13; Streptococcus pneumoniae; United States; antibiotic resistance; antimicrobial resistance; bacteria; bacterial infection; geographic variation; nonvaccine type; penicillin; pneumococcus; serotype; temporal variation; vaccines.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Carrier State
-
Cross-Sectional Studies
-
Humans
-
Mass Vaccination
-
Microbial Sensitivity Tests
-
Penicillin Resistance*
-
Penicillins / pharmacology*
-
Pneumococcal Infections / drug therapy
-
Pneumococcal Infections / epidemiology*
-
Pneumococcal Infections / immunology
-
Pneumococcal Infections / prevention & control
-
Pneumococcal Vaccines / administration & dosage*
-
Prevalence
-
Serogroup
-
Serotyping
-
Streptococcus pneumoniae / classification
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / genetics
-
Streptococcus pneumoniae / immunology
-
United States / epidemiology
-
Vaccines, Conjugate
Substances
-
13-valent pneumococcal vaccine
-
Anti-Bacterial Agents
-
Penicillins
-
Pneumococcal Vaccines
-
Vaccines, Conjugate